In Vitro and In Vivo Studies of the Trypanocidal Properties of WRR-483 against Trypanosoma cruzi | Zendy

YenTing Chen | Zendy; Linda S. Brinen | Zendy; Iain D. Kerr | Zendy; Elizabeth Hansell | Zendy; Patricia S. Doyle | Zendy; James H. McKerrow | Zendy; William Roush | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vitro and In Vivo Studies of the Trypanocidal Properties of WRR-483 against Trypanosoma cruzi

Author(s) -

YenTing Chen,

Linda S. Brinen,

Iain D. Kerr,

Elizabeth Hansell,

Patricia S. Doyle,

James H. McKerrow,

William Roush

Publication year - 2010

Publication title -

plos neglected tropical diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.99

H-Index - 135

eISSN - 1935-2735

pISSN - 1935-2727

DOI - 10.1371/journal.pntd.0000825

Subject(s) - trypanosoma cruzi , cysteine protease , chagas disease , protease , biology , cysteine proteinase inhibitors , in vivo , cysteine , protease inhibitor (pharmacology) , enzyme , biochemistry , virology , programmed cell death , parasite hosting , virus , genetics , apoptosis , world wide web , computer science , antiretroviral therapy , viral load , caspase

Cruzain, the major cysteine protease of Trypanosoma cruzi, is an essential enzyme for the parasite life cycle and has been validated as a viable target to treat Chagas' disease. As a proof-of-concept, K11777, a potent inhibitor of cruzain, was found to effectively eliminate T. cruzi infection and is currently a clinical candidate for treatment of Chagas' disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research